Praxis Precision Medicines, Inc.PRAX

Praxis Precision Medicines, Inc. Segments Disclosure

10-KFiled Feb 19, 20262 min read
Segment Information
The Company has one operating segment. The Company's operating segment discovers and develops therapies for CNS disorders. The Company's chief operating decision maker ("CODM"), its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of assessing performance and
allocating resources based on net loss that also is reported on the consolidated statement of operations as consolidated net loss. Net loss is used by the CODM to make key strategic and operational decisions. The operating segment's revenue is derived from a single domestic collaboration agreement from which the segment licenses certain development or product candidates and has performed research and development services. The measure of segment assets is reported on the balance sheet as total consolidated assets. The majority of the Company's long-lived assets are held in the United States.
The following table presents selected financial information about the Company's single operating segment for the years ended December 31, 2025, 2024, and 2023 (in thousands):
December 31,
202520242023
Collaboration revenue$— $8,553 $2,447 
Program-specific expenses:
Ulixacaltamide(a)
63,207 69,172 19,464 
Vormatrigine74,059 18,360 6,275 
Relutrigine45,951 6,273 3,996 
Elsunersen6,833 2,135 14,595 
         Other early stage assets8,019 4,634 7,055 
Personnel-related expenses64,719 42,853 33,160 
Stock-based compensation expense33,941 41,361 24,857 
Depreciation expense140 358 432 
Other segment expenses(b)
29,329 23,572 18,986 
Other income, net22,930 17,346 3,096 
Consolidated net loss$(303,268)$(182,819)$(123,277)
(a) Includes non-cash research and development of $2.5 million in the year ended December 31, 2024 associated with the Company's collaboration with Tenacia.
(b) Other segment expenses includes research and development and general and administrative costs not attributable to a specific program.

Historical Timeline

Fiscal YearFiled
2025Feb 19, 2026Showing above
2024Feb 28, 2025

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesEarnings Per ShareFair ValuePP&ECommitmentsStock CompensationNew StandardsPay vs Performance